Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma
NCT04931849Phase 1Withdrawn
- Sponsor
- University of Rochester
- Start
- May 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avatrombopag in Thrombocytopenia, sponsored by University of Rochester. Primary endpoint: Safety of treatment at 48 weeks. Planned start May 2022; status: withdrawn.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04931849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931849.